Call Options

7 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$0.48 - $1.33 $816 - $2,261
-1,700 Reduced 13.39%
11,000 $9,000
Q2 2023

Aug 11, 2023

BUY
$1.12 - $1.74 $14,224 - $22,098
12,700 New
12,700 $16,000
Q4 2022

Feb 14, 2023

SELL
$1.7 - $30.2 $345,950 - $6.15 Million
-203,500 Reduced 83.03%
41,600 $73,000
Q3 2022

Nov 14, 2022

BUY
$1.9 - $27.7 $99,370 - $1.45 Million
52,300 Added 27.13%
245,100 $645,000
Q2 2022

Aug 15, 2022

BUY
$1.6 - $3.07 $123,200 - $236,390
77,000 Added 66.49%
192,800 $376,000
Q1 2022

May 16, 2022

BUY
$2.66 - $4.65 $273,980 - $478,950
103,000 Added 804.69%
115,800 $353,000
Q4 2021

Feb 14, 2022

BUY
$4.0 - $12.68 $51,200 - $162,304
12,800 New
12,800 $57,000

Others Institutions Holding EVAX

# of Institutions
1
Shares Held
37.5K
Call Options Held
0
Put Options Held
0

About Evaxion Biotech A/S


  • Ticker EVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 23,977,900
  • Market Cap $20.4M
  • Description
  • Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Ph...
More about EVAX
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.